Amneal Pharmaceuticals (NYSE:AMRX) may soon run out of the raw ingredients to make hydroxychloroquine because Finland is keeping the drug for domestic use, the company’s co-CEOs tell Reuters.
Amneal has committed to producing 20M
hydroxychloroquine tablets by mid-April, but will face challenges making
any more after that because of difficulties acquiring active
ingredients from its supplier in Finland, co-CEOs Chirag Patel and
Chintu Patel say.
Hydroxychloroquine has been promoted by many,
including Pres. Trump, as a potential treatment against Covid-19, and
demand for the drug has soared worldwide to the extent that some
countries such as India have placed restrictions on its export.
Amneal manufactures hydroxychloroquine in India,
and the co-CEOs say the company is working with India to provide an
exception to ship its finished product to the U.S.
https://seekingalpha.com/news/3559986-amneal-running-out-of-hydroxychloroquine-raw-material-co-ceos-say
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.